Hyong Kim Sells Shares of Alignment Healthcare, Inc. (ALHC)
On June 12, 2026, Hyong Kim sold 35,951 shares of Alignment Healthcare.
Key Points
- Hyong Kim, Chief Medical Officer of Alignment Healthcare, sold 35,951 shares valued at $713,986.86 on June 12, 2026.
- Shares of NasdaqGS:ALHC traded near $19.75, with a 52-week range between $11.63 and $23.87.
- Wellington Management Group increased its ALHC holdings by 3,028,043 shares, now holding 17,098,936 shares worth $301 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Hyong Kim, the Chief Medical Officer of Alignment Healthcare, Inc. (NasdaqGS: ALHC), sold 35,951 shares of the company on June 12, 2026. The shares were sold at an average price of $19.86, totaling approximately $713,986.86. This transaction was planned under a Rule 10b5-1 trading plan.
Other Institutional Activity in Alignment Healthcare
Wellington Management Group grew its holdings in Alignment Healthcare by 3,028,043 shares, ending with 17,098,936 shares valued at about $301 million. Similarly, FMR LLC added 1,236,129 shares, bringing its total to 15,892,064 shares worth approximately $280 million. BlackRock, Inc. increased its position by 363,883 shares, reaching 14,075,197 shares valued at $248 million. T. Rowe Price Investment Management, Inc. also boosted its stake by 503,872 shares, now holding 13,147,656 shares valued at $231 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions, each holding 9,710,071 and 7,973,663 shares, respectively.
Alignment Healthcare, Inc. Stock Up 46.8%
Shares of Alignment Healthcare (NasdaqGS: ALHC) traded near $19.75. The company has a market cap of approximately $4.08 billion and a P/E ratio of 197.5. Its forward P/E stands at 27.34, and the stock has a beta of 1.149. The 52-week range for the stock is between $11.63 and $23.87, with a 50-day moving average of $18.62 and a 200-day moving average of $18.61. The company's current ratio is 1.58, and its debt-to-equity ratio is 159.49.
Recent Earnings
Alignment Healthcare reported revenue of $4.26 billion with a revenue growth rate of 33.3%. The company achieved a net margin of 0.47% and a return on equity of 12.53%. Earnings per share stood at $0.10. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
1 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 575.7%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA missed by 28 percent. Operating income missed by 3 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 1 target cut.
-
Earnings quality
Operating margin up 1.8 points. Negative free cash flow.
Earnings Call Summary
Alignment Healthcare reported first quarter 2026 revenue of $1.2 billion, up 33 percent year over year, driven by strong membership growth of 31 percent to 284,800 members. The company beat adjusted EBITDA expectations at $38 million, exceeding guidance range. Management highlighted a temporary January billing issue related to observation versus acute rate payments that caused higher inpatient admissions in early Q1, but stated the problem was internal, quickly resolved by February, and did not signal a systemic flaw. Management remained confident in scaling to 1 million members and emphasized continuous improvement in claims automation, AI deployment, and clinical efficiency.
Guidance Alignment raised its full year revenue guidance to approximately $5.2 billion, up from prior outlook, expecting 31 percent growth. The company also raised adjusted EBITDA guidance, projecting between $138 million and $163 million for 2026. For the second quarter, they guided revenue between $1.3 billion and $1.32 billion and EBITDA of $50 million to $60 million. Management emphasized confidence in delivering the first half at strong margins while continuing investments in automation and clinical infrastructure.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Insider Buying and Selling at Alignment Healthcare, Inc.
On June 12, 2026, Hyong Kim, Chief Medical Officer, sold 35,951 shares at an average price of $19.86. Joseph Konowiecki, EVP of Corporate Affairs, sold 25,000 shares at $21.00 on June 11, 2026. On June 10, 2026, CEO John Kao sold 298,000 shares at $20.36. Earlier, on June 3, 2026, Joseph Konowiecki and Mark Kent, President - MSO, made notable buy transactions, acquiring 122,807 and 87,719 shares respectively.
Analysts Set New Price Targets
On May 26, 2026, Barclays maintained its hold rating on Alignment Healthcare with a price target of $16. UBS also maintained a hold rating with a $22 target on May 1, 2026. Previously, on February 5, 2026, JP Morgan maintained a buy rating with a target of $26. The consensus among analysts is a strong buy recommendation with a mean price target of $24.92 from 13 opinions.
About Alignment Healthcare
Alignment Healthcare, Inc. is a healthcare company focused on providing personalized healthcare solutions for seniors in the United States. It operates through Medicare Advantage plans, aiming to deliver a tailored healthcare experience. Founded in 2013, the company is headquartered in Orange, California, and led by CEO John E. Kao. It employs around 1,849 people.
Bottom Line
Hyong Kim's recent share sale is a planned transaction under a 10b5-1 plan, reflecting strategic financial management. Investors often track insider activities like these to gauge executive confidence in the company's future. While this sale is noteworthy, it's essential to consider the broader context of institutional holdings and analyst perspectives for a comprehensive view of Alignment Healthcare's market position.
Get Alignment Healthcare, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALHC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.